HPV vaccine remains underutilized

August is National Immunization Awareness Month

Karen Miller | 8/15/2014, 5:24 p.m.
Although a vaccine for HPV has been available since 2006, the compliance rate remains low.

The discovery that human papillomavirus, or HPV, causes cervical cancer was a monumental find for which Dr. Haralk zur Hausen, a German scientist, won a Nobel Prize. In 2006 the Food and Drug Administration approved an HPV vaccine for females aged 11 to 12 to guard against cervical cancer as well as genital warts. Those who fail to be vaccinated within that time frame can get “catch-up” shots until the age of 26.

HPV vaccines are given in a series of three shots over six months.

Although HPV is more often associated with cervical cancer — it’s the source of 70 percent of the cases — its damage has a far greater reach. It is the culprit behind other female cancers (vagina and vulva), but males are not exempt. More than 60 percent of penile cancers are attributed to HPV as well as 70 percent of oral cancers, which are more common in males. The virus is responsible for almost all cases of cancer of the anus.

The Centers for Disease Control and Prevention estimates that 65,000 cancers a year are probably attributed to HPV.

In 2011 the Advisory Committee on Immunization Practices recommended the vaccine to boys and young men aged 11 to 21, but males 22 to 26 may also be vaccinated.

HPV is the most common sexually transmitted infection in the country. The CDC estimates that at any given time, roughly 20 million people are infected. Yet, most people remain unaware of these potentially lethal germs. Typically, HPV has no symptoms and is usually eradicated by antibodies found in healthy human immune systems. But some high-risk HPVs, such as HPV 16 and HPV 18, can linger within a body and If not destroyed can result in cancer.

It can take 20 or more years for the disease to develop. That’s why HPV-related cancers tend to strike in the fourth or fifth decade.

Yet, despite the fact that a reliable immunization is readily available, the vaccination rate for HPV in this country is abysmally low. The National Immunization Survey-Teen is a yearly survey that examines immunization rates for adolescents aged 13 to 17. Although there has been a steady increase in compliance with HPV guidelines since 2006, the rates remain much lower than those for other immunizations.

For instance, while 86 percent of the teens covered in the survey had received a dose of Tdap for tetanus, diphtheria and pertussis (whooping cough), only 37 percent of females and 14 percent of males between 13 and 17 had received the full three-shot regimen for HPV.

Particularly troubling were what health professionals call missed opportunities, or health care encounters which included administration of at least one vaccine but not the HPV vaccine. The ACIP recommends administration of all age-appropriate vaccines during a single visit.

Had this recommendation been followed, according to the ACIP, vaccination coverage for at least one dose of HPV vaccine by age 13 could have exceeded 91 percent.

Immunization rates of HPV varied by state, race and income. For females, immunization of at least one dose ranged from 40 percent in Kansas to almost 80 percent in Rhode Island. Similarly in males, coverage ranged from 11 percent in Utah to 69 percent in Rhode Island.